Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 18, 2017; 88 (16 Supplement) April 24, 2017

Evaluation of quantitative EEG as a disease and treatment response biomarker in frontotemporal dementia (P2.083)

Elena Ratti, Sebastian Von Rosenstiel, Shani Waninger, Chris Berka, Mario Mendez, Ajay Verma
First published April 17, 2017,
Elena Ratti
1Biogen Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Von Rosenstiel
1Biogen Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shani Waninger
2Advanced Brain Monitoring Carlsbad CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Berka
2Advanced Brain Monitoring Carlsbad CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Mendez
3VA Greater Los Angeles Healthcare System Los Angeles CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ajay Verma
1Biogen Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Evaluation of quantitative EEG as a disease and treatment response biomarker in frontotemporal dementia (P2.083)
Elena Ratti, Sebastian Von Rosenstiel, Shani Waninger, Chris Berka, Mario Mendez, Ajay Verma
Neurology Apr 2017, 88 (16 Supplement) P2.083;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To assess quantitative electroencephalography (EEG) as a potential disease biomarker for frontotemporal dementia (FTD) drug development.

Background: Recent EEG analysis advances allow non-invasive quantitative evaluation of cortical activity that may detect neurodegeneration. FTD is a neurodegenerative disorder with selective vulnerability of fronto-temporal regions and which lacks established disease progression biomarkers. Previous use of quantitative EEG in FTD has been limited and challenging.

Design/Methods: Resting EEG was acquired at home from two main FTD syndromes (7 behavioral variant FTD (bvFTD), 4 non-fluent variant primary progressive aphasia (nfvPPA)), and compared to 8 normal controls.

Decontaminated EEG data was converted from time to frequency domain using Fast Fourier Transform (FFT). Absolute power spectral densities (PSDs) were calculated for 1 second epochs (1–40Hz bins and standard bandwidths). Neuroguide software was used to compare group PSDs and perform LORETA analyses.

Results: EEG acquisition was feasible for assessing FTD, home assessments facilitated patients’ participation and retention.

Compared to controls, in bvFTD eyes-closed (EC) PSDs showed broadly decrease in alpha and beta activity. Decreases were observed in beta band primarily in frontal and left temporal regions. EC LORETA showed decreased alpha and beta in bilateral temporal and cingulate regions, respectively, and decreased delta in frontal and anterior cingulate areas.

Compared to controls, in nfvPPA EC PSDs showed overall decreased activity, particularly in delta band within central and right temporal regions. EC LORETA showed decreased alpha and beta1 in temporal region and decreased beta2 in temporal and anterior cingulate areas.

Conclusions: Distinctive EEG patterns observed in brain regions typically affected by FTD support the potential of quantitative EEG as a FTD disease biomarker. Differences in EEG patterns between subtypes and other dementias are highlighted. Larger longitudinal and multimodal studies can further evaluate quantitative EEG utility as a disease progression biomarker for application in FTD drug development.

Study Supported by: Biogen

Disclosure: Dr. Ratti has received personal compensation for activities with Biogen as an employee. Dr. Von Rosenstiel has received personal compensation for activities with Biogen as an employee. Dr. Waninger has received personal compensation for activities with Advanced Brain Monitoring. Dr. Wang has received research support from Biogen. Dr. Berka has received personal compensation for activities with Advanced Brain Monitoring (ABM) as an employee. Dr. Berka holds stock in Advanced Brain Monitoring (ABM), which sponsored research in which Dr. Berka was involved as an investigator. Dr. Berka has received research support from Biogen. Dr. Mendez has received personal compensation in an editorial capacity for UpToDate. Dr. Verma has received personal compensation for activities with Biogen as an employee. Dr. Verma has stock and/or stock options in Biogen.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (3)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise